News
20 August 2008
ImmunoVEXHSV2 cleared to enter clinic
BIOVEX REPORTS POSITIVE PHASE II CLINICAL TRIAL
RESULTS OF ONCOVEXGM-CSF IN METASTATIC
MELANOMA AT THE 2008 AMERICAN SOCIETY OF CLINICAL ONCOLOGY MEETING
Chicago, IL – June 1, 2008
BioVex Inc, a biotechnology company
developing clinical stage treatments for cancer and the prevention
of infectious disease, today announced positive results from
its Phase II clinical trial of OncoVEXGM-CSF,
an oncolytic for the treatment of advanced metastatic melanoma,
at the 2008 Annual Meeting of the American Society of Clinical
Oncology (ASCO) in Chicago, IL.
+ read more
BIOVEX AGREES SPA WITH THE FDA FOR A PIVOTAL STUDY
WITH ONCOVEXGM-CSF IN METASTATIC MELANOMA
AND ANNOUNCES PRESENTATION OF PHASE II RESULTS AT ASCO
FDA agrees to first SPA for an oncolytic product
Woburn, MA, April 22nd, 2008 BioVex
Inc announced
today that the U.S. Food and Drug Administration (FDA) has approved
the design of a single, pivotal, Phase III clinical trial evaluating
its lead product, OncoVEXGM-CSF in
previously treated patients with metastatic melanoma. The agreement
was made under the special Protocol Assessment (SPA) procedure. +
read more
|
